STAT June 3, 2024
Elaine Chen

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma / Biotech, Trends
Navigating Complex Regulatory Landscapes in the Biopharmaceutical Industry
How Life Sciences Can Drive Innovation And Sustainability In Returns Management
10X Genomics at JPM: New Products, New Sales Team, New Markets
Enhancing Target Screening with CRISPR Libraries: Revolutionizing Drug Discovery and Functional Genomics
Daiichi Sankyo Announces New CEO

Share This Article